Compare Amgen, Inc. (AMGN) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Grab Holdings Ltd. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Grab Holdings Ltd. trades at $3.95 (market cap $16.07B). The key difference: Amgen, Inc. is far larger — about 12.2× Grab Holdings Ltd.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| AMGN | GRAB | |
|---|---|---|
Market Cap | $196.12B | $16.07B |
Sector | Health | Technology |
52-Week High | $388.16 | $6.45 |
52-Week Low | $271.18 | $3.27 |
Enterprise Value | $241.41B | $11.77B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Grab Holdings trades at $3.93, up 1.29% with a bullish technical signal. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing strong revenue growth from $2.8B to $3.4B. Analyst consensus is strongly bullish with 11 buy ratings and a $5.45 price target, representing 39% upside potential. Recent news highlights investor interest despite Uber CEO's board departure causing temporary volatility.
Grab presents a compelling growth story with improving fundamentals and strong analyst support. Key opportunities include Southeast Asia market expansion and super-app ecosystem growth. Risks include intense competition, execution challenges, and market volatility. The stock offers significant upside to consensus targets but requires monitoring of quarterly execution and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
